French veterinary pharmaceutical firm Virbac (VIRB.PA) reported a jump in first-half earnings on Monday but trimmed its 2016 revenue growth forecasts due to difficulties in the United States and Chile, as well as a negative currency impact.
The company, which sells drugs for animals in more than 100 countries, is now aiming for organic revenue growth of 4.5-6.5 percent in 2016 compared with a previous target of 7 percent, it said in a statement.
12:23 Sterling volatile as market speculates on ‘hard Brexit’; investors await May's speech15
01:03 Sterling slides to three-month lows on 'hard Brexit' fears13
22:15 Sterling skids on Brexit anxiety; investors hope for Donald Trump clarity15
15:04 Hoping to save a 20 percent down payment? It's a big chunk of change15